Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two

Neuromuscular Disorders

Volumn 19, Issue 3, 2009, Pages 223-228

  Schoser, Benedikt ^a   Jacob, Saiju ^b   Hilton Jones, David ^b   Müller Felber, Wolfgang ^a   Kubisch, Christian ^c   Claus, Detlef ^b   Goebel, Hans H ^d   Vita, Giuseppe ^e   Vincent, Angela ^b   Toscano, Antonio ^e   Bergh, Peter Van den ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Neuroimmunology ^*  (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF MESSINA   (Italy)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Caveolin 3; Immunogenic; Myasthenia gravis; Rippling muscle disease; Therapy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CAVEOLIN 3; CHOLINESTERASE INHIBITOR; DYSFERLIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MUSCLE PROTEIN; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNE MEDIATED RIPPLING MUSCLE DISEASE; IMMUNOFLUORESCENCE TEST; MALE; MOLECULAR WEIGHT; MUSCLE DISEASE; MYALGIA; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; SARCOLEMMA; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; AUTOANTIBODIES; AZATHIOPRINE; CAVEOLAE; CAVEOLIN 3; CHOLINESTERASE INHIBITORS; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYASTHENIA GRAVIS; PLASMAPHERESIS; STEROIDS; THYMUS GLAND;

EID: 61849131672     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.01.002     Document Type: Article

References (27)

1. Torbergsen T. A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita Thomsen. Acta Neurol Scand 51 3 (1975) 225-232
2. Betz R.C., Schoser B.G., Kasper D., Ricker K., Ramirez A., Stein V., et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 28 3 (2001) 218-219
3. Woodman S.E., Sotgia F., Galbiati F., Minetti C., and Lisanti M.P. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62 4 (2004) 538-543
4. Vorgerd M., Bolz H., Patzold T., Kubisch C., Malin J.P., and Mortier W. Phenotypic variability in rippling muscle disease. Neurology 52 7 (1999) 1453-1459
5. Kubisch C., Schoser B.G., von During M., Betz R.C., Goebel H.H., Zahn S., et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 53 4 (2003) 512-520
6. Vorgerd M., Ricker K., Ziemssen F., Kress W., Goebel H.H., Nix W.A., et al. A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 57 12 (2001) 2273-2277
7. Ricker K., Moxley R.T., and Rohkamm R. Rippling muscle disease. Arch Neurol 46 4 (1989) 405-408
8. Parton R.G., and Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 8 3 (2007) 185-194
9. Kubisch C., Ketelsen U.P., Goebel I., and Omran H. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol 57 2 (2005) 303-304
10. Ansevin C.F., and Agamanolis D.P. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol 53 2 (1996) 197-199
11. Ashok Muley S., and Day J.W. Autoimmune rippling muscle. Neurology 61 6 (2003) 869-870
12. Ansevin C.F. Phenotypic variability in rippling muscle disease. Neurology 54 1 (2000) 273-274
13. Muller-Felber W., Ansevin C.F., Ricker K., Muller-Jenssen A., Topfer M., Goebel H.H., et al. Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis. Neuromuscul Disord 9 8 (1999) 604-607
14. Greenberg S.A. Acquired rippling muscle disease with myasthenia gravis. Muscle Nerve 29 1 (2004) 143-146
15. Schulte-Mattler W.J., Kley R.A., Rothenfusser-Korber E., Bohm S., Bruning T., Hackemann J., et al. Immune-mediated rippling muscle disease. Neurology 64 2 (2005) 364-367
16. Takagi A., Kojima S., Watanabe T., Ida M., and Kawagoe S. Rippling muscle syndrome preceding malignant lymphoma. Int Med 41 2 (2002) 147-150
17. Watkins T.C., Zelinka L.M., Kesic M., Ansevin C.F., and Walker G.R. Identification of skeletal muscle autoantigens by expression library screening using sera from autoimmune rippling muscle disease (ARMD) patients. J Cell Biochem 99 1 (2006) 79-87
18. Maselli R.A., Richman D.P., and Wollmann R.L. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 41 9 (1991) 1497-1504
19. Buckley C., and Vincent A. Autoimmune channelopathies. Nat Clin Prac Neurol 1 (2005) 22-33
20. Fischer D., Schroers A., Blumcke I., Urbach H., Zerres K., Mortier W., et al. Consequences of a novel caveolin-3 mutation in a large German family. Ann Neurol 53 2 (2003) 233-241
21. Van den Bergh P.Y., Gerard J.M., Elosegi J.A., Manto M.U., Kubisch C., and Schoser B.G. Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease. J Neurol Neurosurg Psychiatry 75 9 (2004) 1349-1351
22. Hernandez-Deviez D.J., Martin S., Laval S.H., Lo H.P., Cooper S.T., North K.N., et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 15 1 (2006) 129-142
23. Schubert W., Sotgia F., Cohen A.W., Capozza F., Bonuccelli G., Bruno C., et al. Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am J Pathol 170 1 (2007) 316-333
24. Walker G.R., Watkins T., and Ansevin C.F. Identification of autoantibodies associated with rippling muscles and myasthenia gravis that recognize skeletal muscle proteins: Possible relationship of antigens and stretch-activated ion channels. Biochem Biophy Res Commun 264 (1999) 430-435
25. Buckley C., Newsom-Davis J., Willcox N., and Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?. Neurology 57 9 (2001) 1579-1582
26. Parker S., Peterkin H.S., and Baylis H.A. Muscular dystrophy associated mutations in caveolin-1 induce neurotransmission and locomotion defects in Caenorhabditis elegans. Invert Neurosci 7 3 (2007) 157-164
27. Carlson B.M., Carlson J.A., Dedkov E.I., and McLennan I.S. Concentration of caveolin-3 at the neuromuscular junction in young and old rat skeletal muscle fibers. J Histochem Cytochem 51 9 (2003) 1113-1118